Martikainen, Janne A.; Kivioja, Akseli; Hallinen, Taru; … - In: PharmacoEconomics 23 (2005) 8, pp. 803-815
Background: Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma. TMZ has widely replaced the procarbazine, lomustine plus vincristine (PCV) combination for the treatment of malignant brain tumours as a...